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approach to costing and uptake among populations considered. CONCLUSIONS:
Rx-to-OTC switches are a real opportunity to realise savings for budget holders and
productivity gains for employers. More robust economic models are required to
estimate the impact of the switches in Europe.
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OBJECTIVES: Health policy and funding for medications classed as ‘lifestyle’ have
received considerable scrutiny by public health officials as well as politicians. This
has limited public funding and reimbursement for these products in many Euro-
pean countries. A detailed assessment of the variation in payer coverage polices for
lifestyle medications across Europe was conducted. METHODS: The top ‘lifestyle’
indications and associated medications were identified from a literature search
using WHO, PubMed, and ScienceDirect. Selection criteria for the medications in-
cluded being first-to-market in the identified indication or being referenced as the
only off-label treatment for the specified use. Public reimbursement databases (16)
were used to analyze the health technology assessment and reimbursement deci-
sions across European countries (14) for each lifestyle indication. Reimbursement
was classified as favourable (broad/restricted but accessible) or no coverage (not
funded). Where available, justifications for coverage decisions were analysed to
determine the drivers of positive and negative coverage decisions. RESULTS: Life-
style indications where products have achieved high levels of reimbursement in-
clude Dyspepsia (100%), Delaying Menstruation (91%), Restless Leg Syndrome
(87%), and Alcohol Dependence (85%). Those with the worst coverage are Hair Loss
(0%), Hypoactive Sexual Desire Disorder (0%), Erectile Dysfunction (13%), and
Weight Loss (15%). Of the 14 countries researched, those offering the most favour-
able coverage environments for lifestyle treatments were: Belgium (70%), France
(69%), and Austria (69%). The countries with the most limited (no available) cover-
age for lifestyle drug therapies were The Netherlands (13%) and Sweden (25%). Four
general characteristics are associated with better access to market: Cross-Usage in
Other Indications, Areas with High Societal Costs, Diseases that Affect Family Plan-
ning, and Older Therapy Areas. CONCLUSIONS: With pressure on public health
resources, European payers are resistant to the allocation of funds for medications
with lifestyle indications. Despite this, barriers to reimbursement vary substan-
tially across European markets.
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OBJECTIVES: This study seeks to evaluate the impact of the 2011 German health-
care reform (AMNOG) on the global pricing and reimbursement landscape and its
influence, if any, on global market access strategies. METHODS: Key local regula-
tors were interviewed to understand the scope and mechanism of the mandatory
early benefit assessment as well as its implications in terms of pricing and market
access on a national and global level. Primary research consisted of in-depth phone
interviews with six regulatory stakeholders and industry representatives in Ger-
many. Secondary research was based on data from national and regional health-
care authorities, national statistics offices and IHS Global Insight Healthcare and
Pharmaceutical services. RESULTS: AMNOG has put an end to free pricing in Ger-
many by correlating price to added therapeutic benefit scores and opening the
reference pricing system to all patented medicines. The total transparency of the
early benefit assessment and pricing processes can influence prices not only in
Europe but also worldwide. The availability of results from the Federal Joint Com-
mittee (G-BA)’s benefit assessment can affect the pricing and reimbursement sta-
tus of pharmaceuticals worldwide, while international reference pricing can put
downward pressure on prices in at least 22 other countries. CONCLUSIONS: The
German reform will have an impact beyond the country’s borders. Germany has
traditionally been an early pharmaceutical launch market but the end of free pric-
ing and the prospect of lower price levels for products of no and minor-to-moderate
added value may require a complete reconsideration of the optimal launch se-
quence. While AMNOG has revolutionized the pricing and reimbursement land-
scape in Germany, from a global perspective, the reform is not particularly inno-
vative. Germany’s new pricing process is comparable to the French model whereby
perceived degree of innovation directly impacts medicine prices, and comes near
to the Swiss and Austrian models.
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OBJECTIVES: This analysis compares pricing levels across 15 European countries
and 10 therapy areas in 2010. The differences in the price levels are related to
parallel imports and the innovativeness of prescriptions. METHODS: From IMS
PRICING INSIGHTS pricing information for pharmaceutical products is accessed at
the pack level from 15 countries (EU5-Austria-Ireland-Sweden-Norway-Denmark-
Portugal-Greece-Poland-Hungary-Romania) for 2010. Currency rates are fixed at
2010 levels. For the ten therapy areas, product baskets are constructed for the
comparisons: The therapy areas are defined as Anatomic-Therapeutic-Chemical
(ATC) classes at level 2. The top 100 products by sales in the EU5 in these classes
enter the comparisons. Prices are compared at the manufacturer and the public
sales levels. IMS MIDAS identifies imports related to the products in the baskets.
The innovativeness of products is operationalized as the number of months be-
tween the overall first introduction and the introduction in the countries.
RESULTS: The first result is that international drug price comparisons are ex-
tremely sensitive to methodological issues, e.g. sample selection, exchange rates.
Differences in price build-up structures between countries would dominate cross-
country price differences, if not accounted for. Differences between countries exist
at the ex-manufacturer-level, differences between public sales levels tend to be
larger. Price level differences between countries are not consistent across all ana-
lyzed therapy areas. Higher price levels are related to parallel trade rates across
countries and to an earlier access to new pharmaceutical products.CONCLUSIONS:
The analysis shows price differences across countries related to manufacture pric-
ing and regulation structuring the price build-up and taxes. Higher price levels are
linked to an earlier access to innovative products. Parallel trade flows into coun-
tries with higher price levels, usually from countries with lower price levels, caus-
ing scarcities. Differences in economic development and purchasing powers need
to be analyzed to evaluate these differences in pricing levels.
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OBJECTIVES: Value assessment of interventions is conducted in some form or the
other, although the importance given to different domains of decisions differ by
markets. The research is aimed to analyse how perspectives on value assessment
of pharmaceuticals or device interventions vary across regions. The research also
analysed how products at launch increase the chances of approval, shorten time to
reimbursement and remain competitive within the value based pricing agenda.
METHODS: The research involved desk research as well interviews with key influ-
encers and decision makers in major markets beyond Europe. More than 25 tele-
phone or face to face interviews with key stakeholders were conducted. RESULTS:
The research indicated that most countries, other than those that use international
price referencing for setting prices use some form of value assessment method
before fixing the reimbursement level and price of the product. The decisions are
predominantly based on level of unmet needs, severity of diseases, level of inno-
vation, clinical differentiation of the new product against its comparators and how
well the product finds it natural place in the treatment pathway. Many forward
regions claim to use value based assessments to set the price of new launches,
most operate within boundaries. In principal value based pricing should not be
fenced with limitations such as cost/QaLY thresholds, budget impact and price-
volume agreements. However in real life these measures are common in markets
all over the world, the main reason being the limitations in health care budgets.
CONCLUSIONS: It is very challenging to reward products based on their intrinsic
value without introducing other hurdles within the current economic environ-
ment. However it also is critical to reward innovation for future investments in
R&D of new drugs. Health care reforms in the future will raise the bar of innovation
and differentiation making it more challenging for the Pharmaceutical industry
and all those involved in developing new medicines.
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OBJECTIVES: EuSANH is a network of science advisory bodies in Europe. The proj-
ect Eusanh-ISA is funded by 7th framework programme of DG Research. It aims to
improve the quality, effectiveness and efficiency of science advice for health across
Europe. Within this project the objective of this work is to learn about the percep-
tions of policy-makers (PM) and science advise bodies’ (SAB) staff concerning the
relationship between these two groups, and the current use of science advice (SA)
in policy making.METHODS: Two questionnaires were designed targeting both PM
involved in developing health policy (such as government ministers, officials and
senior public servants within national and/or local health services) and senior staff
with extensive experience working in a SAB. The questionnaire was sent to 25 PM
and to 29 SAB staff. Descriptive analysis was carried out. RESULTS: Nineteen PM (3
Belgium, 1 Czech Republic, 1 Lithuania, 2 the The Netherlands, 2 Poland, 1 Roma-
nia, 5 Spain, 3 Sweden and 1 UK) and 25 SAB staff (1 Belgium, 1 Czech Republic, 1
Italy,1 Lithuania, 4 the The Netherlands, 1 Poland, 3 Romania, 11 Spain, and 2 from
Sweden) responded the questionnaire. Factors seen as barriers for the relationship
between PM and SAB are the differences in timing, interest, and difficulties to
translate policy problems into research questions. The communication was seen
as informal. PM and SAB considered that usefulness of SA could be improved with
more clarity, brevity, simplicity and concise reporting. Transparency, indepen-
dency, existence of procedures to adequately deal with conflict of interest, rigor
and systematization of knowledge are factors ranked with highest value.
CONCLUSIONS: Proposals to improve the SA process are “organising regular high
level meetings” and “improve the trust between decisors and researchers”.
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OBJECTIVES: Fifteen committees currently undertake drug evaluations at the re-
gional level in Spain that serve as the basis for pharmaceutical policy decisions
within primary care or specialized care above single hospitals. The objective of this
study was to examine the quality of the assessment procedures under which drug
evaluations are undertaken by these regional committees. METHODS: We ana-
lyzed the quality of the assessment procedures on the basis of 4 criteria: whether
operating procedures (OP) are public, whether there is dialog with the marketing
authorization holder (MAH) during the assessment, whether drug assessments are
public, whether a full economic evaluation (EE) (i.e. costs and health outcomes are
taken into account) is undertaken. We reviewed all the public information regard-
ing OPs and drug assessments undertook by these committees. Search was con-
ducted in Google, official bulletins and official Regional Health Systems websites,
with no limits. RESULTS: In primary care, 2 out of 8 committees follow a public OP
when assessing a new drug and explicitly have interaction with the MAH during
the assessment. All the committees publish their assessments but none of them
undertake full EEs (e.g. only drug costs are considered). Within specialized care 3
out of 7 committees follow a public OP, 2 of which interact with the MAH. 3 com-
mittees publish their assessments and also 3 undertake full EEs. Overall 33% of
committees follow a public OP, 27% have interaction with the MAH during the
assessment, 73% publish their assessments and 20% undertake a full EE.
CONCLUSIONS: There is room for improvement in the work undertaken by re-
gional drug evaluation committees regarding transparency of OPs, dialog with the
MAH and use of EE as a tool for informing decision making.
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OBJECTIVES: This study seeks to evaluate the impact on market access for phar-
maceuticals in the UK following the introduction of Value Based Pricing (VBP).
METHODS: SMC advice and final NICE guidance issued between 1 June 2010 and 31
May 2011 were assessed to determine the number and outcome of total appraisals,
of Single Technology Appraisals (STAs), and of appraisals based on a manufacturer
submission. The current duration of a NICE STA review and the time required to
provide guidance under the NICE Scientific Advice Programme were also reviewed.
RESULTS: Under VBP, all new originator drugs entering the market and all new
indications of existing medicines will be reviewed: as is the case currently in Scot-
land. Over the 12-month period, the SMC reviewed a total of 101 new drugs or
indications, of which 18 were resubmissions, so a total of 83 original reviews were
performed. NICE – which only reviews treatments it is commissioned to review by
the DH – conducted 28 STAs. Some 47% of SMC drug reviews resulted in positive
guidance – rising to 58% among reviews based on a manufacturer submission. The
average length of a NICE technology appraisal is 18 months; however, NICE scien-
tific guidance can be provided in as little as 15 weeks. CONCLUSIONS: Pharmaceu-
tical market access in England and Wales will potentially improve following the
introduction of VBP as more products are reviewed in a more timely manner. Three
times more originator medicines or new indications will be reviewed in compari-
son to the number currently reviewed by NICE. The average duration of an ap-
praisal under VBP could to be just 15 weeks – 19.2% of the time currently required.
On the negative side, manufacturers would be expected to offer products at an
acceptable price – calculated in accordance with yet-to-be-finalised criteria – in
exchange for gaining reimbursement.
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OBJECTIVES: Many countries have to face policy dilemma between cost contain-
ment policy and industry policy which may encourage pharmaceutical firms in
terms of R&D. This study is trying to investigate the following issues: firstly, it tries
to figure out the major determinants of R&D investment of pharmaceutical firms.
Secondly, it compares the effects of those determinants on R&D intensity between
U.S. and the rest of the world. METHODS: Using a 10 year panel dataset extracted
from several sources such as Compustat, KISINFO, PhRMA, and JPMA, this study
empirically investigates whether US pharmaceutical market which is relatively
unregulated has higher profitability and cash flows than its counterparts where
drug prices are regulated by government agencies. Employing OLS, random-effects,
and fixed-effects specifications for established R&D investment models from the
literature, the study tries to explore the links between pharmaceutical price regu-
lation and firm R&D investment intensity. RESULTS: Data from 32 major pharma-
ceutical firms have been collected for the years 2000 through 2009, and several
models of the determinants of R&D investment were estimated. The regression
results show that expected profits and lagged cash flows are principal determi-
nants of firm R&D-to-sales ratios. It has been argued that pharmaceutical price
regulation influences R&D investment through both of these channels, resulting in
an expected-profit effect and a cash-flow effect. The former influences R&D con-
temporaneously while the latter effect operates with at least 1 year lag. From a
comparison of effects on R&D intensity, U.S. has about 4 or 5 times higher profit-
ability effect than non-U.S. where pharmaceutical price regulation is so strictly
implemented. CONCLUSIONS: A slower R&D growth as a consequence of price
regulation may be politically acceptable because current consumer can benefit, but
we can predict that the cost to the future generations is substantial.
PHP40
PERCEPTION STUDY OF UNDERGRADUATES TOWARDS MEDICINES – A SURVEY
Udupa N1, Dharmagadda S2, Ligade V2, Muragundi PM2
1Manipal University, Manipal, Karnataka State, India, 2Manipal College of Pharmceutical
Sciences, Manipal, India, India
OBJECTIVES: To know the perception of undergraduate students about various
aspects (Cost, quality and safety) of over-the-counter and prescription medicines.
METHODS: Structured, non-disguised, pretested self-administered questionnaire
was used for the study. The total sample was 200 undergraduates (Group 1 – 100
science graduates and Group 2 – 100 arts graduates). ‘t’ Test was used to analyze the
data. RESULTS: Most of the science graduates (78%) have expressed the cost of
medicines were affordable and feel appropriate. They expressed Research and
Development and manufacturing requires huge money and time, hence the cost.
On the quality front, most of the respondents (68%) were satisfied. However, as far
as safety is concerned, many respondents (79%) have expressed that they are safe
as they pass through several phases of clinical trials. They were in an opinion that
over-the-counter medicines are safer than the prescription medicines. Whereas
most of the arts graduates (84%) have said that cost of medicines are higher and
were not having any idea about the research, development and manufacturing
costs involved. Many respondents (87%) said that quality is just acceptable. Quite a
few respondents (69%) said that medicines are not safe and have to be taken with
caution, whether it is over-the-counter or prescription medicines. CONCLUSIONS:
Significant differences were noted between two groups of respondents. Sciences
graduates feel the cost charged on medicines is appropriate, are of right quality and
often safe. Whereas arts graduates were affirmative to quality and safety aspect
but were in opinion that costs charged on medicines are higher.
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OBJECTIVES: It has been reported that 50-65 % of the Indian population has no
access to essential medicines, whereas a small portion of the population using
medicines, do so irrationally and unnecessarily. Irrational use of medicines leads to
wastage of national wealth and also emerging Adverse Drug Reactions (ADRs) and
developing resistance to some drugs especially antibiotics. In order to improve the
situation, several interventions have been suggested. One such intervention is
promoting the concept of Rational Use of Medicines (RUM) through conducting
workshops and seminars involving all stake holders in the health care system. This
study was conducted to determine the effect of an intervention on drug use pattern
in a community.METHODS: Study was conducted in the semi urban areas covering
three districts of West Bengal, India. Community pharmacies mainly serving the
prescriptions of private practioners were involved in this study. Prescriptions were
collected from community pharmacies, serving prescriptions of private practitio-
ners in a semi urban area within a month. 30 prescriptions each from 10 pharma-
cies were collected from the area where workshop/seminars were conducted dur-
ing the last two years. 30 prescriptions each from 10 pharmacies were collected
where no such workshop/seminars were organized for the past two years.
RESULTS: Results show that the average number of medicines prescribed per en-
counter reduced from 2.84 to 2.18. % of prescriptions for generics improved signif-
icantly from nil to 22.78. % of prescriptions for antibiotics and vitamin tonics re-
duced significantly, i.e. from 54.33 to 34.66 and from 16 to 12 respectively, % of
prescriptions for injections reduced from 3.66 to 0.33 .Average number of FDCs
reduced from 1.13 to 0.55. CONCLUSIONS: It reveals from the result mentioned
above that medicine use indicators have improved significantly by intervention i.e.
disseminating information on rational use of medicines amongst the stake holders
of a health care system.
PHP42
DRUG CONSUMPTION IN BOSNIA AND HERZEGOVINA - COMPARISON TO
NEIGHBORING COUNTRY
Krehic J1, Gavrankapetanovic F1, Djapo M2, Agic N3
1Clinical Center University of Sarajevo, Sarajevo, Bosnia, 2Health Insurance Fund, Canton
Sarajevo, Sarajevo, Bosnia, 3Federal Health Insurance Fund, Sarajevo, Bosnia
OBJECTIVES: To identify differences in drug consumption in two neighbouring
countires, B&H with decentralized HC system and Croatia with centralized HC
system.METHODS: In this research we have studied 12 reimbursement lists in B&H
and 1 in Croatia. In 2009, in B&H, the total drug consumption was 467 mBAM, or
37.6% of drug consumption in the same year in Croatia (43.6% if adjusted for num-
ber of inhabitants, and 37.9% if adjusted for VAT and number of inhabitants). All
drugs were included in the analysis irrespectively of the co-payment and prescrip-
tion status (retail or hospital) and were grouped based on ATC level 3 and INN. Top
ten ATC 3 groups with highest expenditure in 2009 were identified and cross ref-
erenced with top ten in HR. For these groups BH spent 45% of its combined medi-
cine budget and HR spent 37%. RESULTS: The most significant differences in the
share of relevant ATC 3 group in the total drug expenditure were observed for
antihypertensive drugs: C09B (5,9% BH; 3,0% HR), C09A (4,6% BH; 2,5% HR), anxiolyt-
ics: N05B (3,4% BH; 1,0% HR) and beta-lactam antibiotics: J01C (3,2% BH; 1,5% HR).
High share of drug expenses related to C09B and C09A groups can be explained by
very high cardiovascular mortality rate, causing 2,5 time more deaths each year
than malignant diseases. In BH we also observed very low consumption share of
statins C10A (2,0% BH; 4,5% HR) and antipsychotics N05A (1,8% BH; 3,7% HR). In
spite of restrictive policies regulating availability of oncology medicines to pa-
tients, we did not observe significant difference in L01X (4,3% BH; 5,2% HR).
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